Quantitative Clinical Pharmacology of CAR T-Cell Therapy

Affiliations

¹ Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
² EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA.
³ Certera QSP, Certara UK Ltd., Sheffield, UK.
⁴ Leiden University, Leiden, The Netherlands.

Editorial

Sarah A Holstein et al. Clin Pharmacol Ther. 2022 Jul.

. 2022 Jul;112(1):11-15.

doi: 10.1002/cpt.2631.

¹ Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
² EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA.
³ Certera QSP, Certara UK Ltd., Sheffield, UK.
⁴ Leiden University, Leiden, The Netherlands.

No abstract available

Comment on

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K, Lymp J, Mack T, Dell'Aringa J, Huang CP, Smith J, Peiser L, Kostic A. Ogasawara K, et al. Clin Pharmacol Ther. 2022 Jul;112(1):81-89. doi: 10.1002/cpt.2561. Epub 2022 Mar 20. Clin Pharmacol Ther. 2022. PMID: 35156195 Free PMC article.

1. Holstein, S.A. & Lunning, M.A. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin. Pharmacol. Ther. 107, 112-122 (2020).
1. Stein, A.M. et al. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacometrics Syst. Pharmacol. 8, 285-295 (2019).
1. Ogasawara, K. et al. In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed/refractory large B-cell lymphoma. Clin. Pharmacol. Ther. 112 81-89 (2022).
1. Abramson, J.S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839-852 (2020).
1. Awasthi, R. et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 4, 560-572 (2020).